AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Identifying common mistakes in retirement planning can save you from future pitfalls. Learn what to avoid for a secure retirement.
14,327 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Community bankers push for a renewed review of Kraken Financial's Fed account, arguing a tightening assessment could ...
Ethereum trades at a level that many long-time holders never imagined, sparking questions about the next move. This a...
GameStop’s walking away from a massive pay package marks a dramatic pivot as the company uses its stock to press a bi...
Micron Technology surged to a fresh all-time high after a blockbuster earnings report and strong AI-driven demand. Th...
X-Energy stock faced a sharp 19.2% drop this week after project delays and a downgrade. This article breaks down the ...
OpenAI reportedly considers delaying its IPO, placing AI stocks in the spotlight. This guide breaks down the potentia...
NVIDIA CEO Jensen Huang told investors that AI-powered supercomputing could become a common feature in homes within y...
Archer Aviation rode the eVTOL thrill, but reality check milestones have tempered the hype. This guide helps you deci...
UiPath edges higher as investors monitor its agentic automation strategy ahead of earnings. This analysis breaks down...
Investors are buzzing about a SpaceX and TESLA merger. This piece dives into what a deal could mean for AI, energy, a...
A surge in Lemonade's stock grabbed attention as investors weighed renewed reinsurance terms and AI-driven growth. Th...